We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ANI Pharmaceuticals Inc | NASDAQ:ANIP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.07 | 0.10% | 67.18 | 67.15 | 67.18 | 67.93 | 66.6467 | 67.72 | 57,282 | 20:35:43 |
From May 2021 to May 2024
By Chris Wack
ANI Pharmaceuticals Inc. said it has received Food and Drug Administration approval for the abbreviated new-drug application for rifabutin capsules USP, 150 mg.
The company said its rifabutin capsules are the generic version of the reference listed drug Mycobutin.
The current annual U.S. market for rifabutin capsules USP, 150 mg is about $16.6 million, according to IQVIA/IMS Health.
ANI Pharma said it plans to launch rifabutin capsules immediately.
ANI Pharma shares were up 7% to $50 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 21, 2021 07:25 ET (12:25 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year ANI Pharmaceuticals Chart |
1 Month ANI Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
